Nazha, A., Sekeres, M. A., Bejar, R., Rauh, M. J., Othus, M., Komrokji, R. S., … Maciejewski, J. P. (2019). Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. JCO PRECISION ONCOLOGY, 3. https://doi.org/10.1200/P0.19.00119

Nazha, Aziz, Mikkael A. Sekeres, Rafael Bejar, Michael J. Rauh, Megan Othus, Rami S. Komrokji, John Barnard, et al. “Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence.” JCO PRECISION ONCOLOGY 3 (2019). https://doi.org/10.1200/P0.19.00119.

Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, et al. Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. JCO PRECISION ONCOLOGY. 2019;3.

Nazha, Aziz, et al. “Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence.” JCO PRECISION ONCOLOGY, vol. 3, 2019. Wos-lite, doi:10.1200/P0.19.00119.

Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP. Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. JCO PRECISION ONCOLOGY. 2019;3.